Humoral responses to the CoronoVac vaccine in healthcare workers
Open Access
- 1 January 2023
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 56, e0209
Abstract
This study aimed to assess the immunoglobulin G (IgG) antibody response rate in emergency department (ED) healthcare workers (HCWs) and potential adverse effects after CoronaVac vaccination. All included HCWs were grouped based on the previous history of coronavirus disease 2019 (COVID-19) and the number of vaccinations. Furthermore, the IgG antibody response was evaluated based on the sex and smoking status of HCWs. Those with a cut-off index of ≥1.00 after vaccination with CoronaVac were considered to have had COVID-19 and had an adequate humoral response. Among 224 ED HCWs, 18% experienced the adverse effects of CoronaVac vaccine, the most prevalent being pain in the injection site. The IgG antibody response rate was 20% after the first dose of vaccine, while the response rate increased to 90% after the second dose. Female HCWs had higher IgG response rates compared with male HCWs (53.8 [15.9-147.0] vs 31.2 [4.5-124.0]). Non-smokers had higher IgG response rate compared with smokers (49.0 [11.5-160.5] vs 23.1 [7.4-98.5]). A single dose of CoronaVac does not produce a sufficient antibody response; hence, two doses are recommended. Men have a lower IgG response compared with women. Smokers had a lower IgG response rate compared with non-smokers. Therefore, it may be necessary to carefully assess the humoral responses of men and smokers when implementing a community vaccination program.Keywords
This publication has 13 references indexed in Scilit:
- Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control studyThe Lancet Regional Health - Americas, 2021
- The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination—An Analysis of Serological Response and Side EffectsVaccines, 2021
- SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?Advanced Drug Delivery Reviews, 2021
- A Comprehensive Review of the Global Efforts on COVID-19 Vaccine DevelopmentACS Central Science, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Platforms Exploited for SARS-CoV-2 Vaccine DevelopmentVaccines, 2020
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020MMWR. Morbidity and Mortality Weekly Report, 2020
- Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2Journal of Clinical Microbiology, 2020
- COVID‐19 diagnosis and management: a comprehensive reviewJournal of Internal Medicine, 2020
- Cigarette smoking differentially affects immunoglobulin class levels in serum and saliva: An investigation and reviewBasic & Clinical Pharmacology & Toxicology, 2019